• Expert Guidance
  • Get Help
  • Patient Stories
  • About Us
    • Our Story
    • Meet the Team that Cares
    • Distinguished Advisors
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Support Our Mission
  • Expert Guidance
  • Get Help
  • Patient Stories
  • About Us
    • Our Story
    • Meet the Team that Cares
    • Distinguished Advisors
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Support Our Mission
 

Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma

July 28, 2021
Focus: Brain Cancer
Topics: Treatment Options

Oncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.

.

.

Tags: glioma, oncolytic virus, teserpaturev

Our Mission: Cancer Commons is a non-profit network of patients, scientists, and physicians united by a shared goal—to optimize each patient’s outcome and maximize collective learning to benefit the next patient.

Don’t miss Cancer Commons Connects
Insights and stories—from and for our community

Working.

Our Services

  • Expert Guidance
  • Register with Cancer Commons

Learn More

  • About Your Cancer
  • Curious Dr. George
  • Patient Stories & Outcomes
  • Testimonials

About Us

  • Our Story
  • Our Team
  • Board of Directors
  • Partners
  • Careers
  • Financial Documents
  • Contact Us

Support & Giving

  • Contribute Now
  • Support Expert Guidance for Cancer Patients


Donate

Cancer Commons
2625 Middlefield Road Suite 104
Palo Alto, CA 94306

650-289-4044

Patient Hotline

877-971-1200

  • Privacy Policy

© 2025 Cancer Commons.